Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 3, 2013, Pages 1144-1149

  Bhalodi, Amira A ^a   Papasavas, Pavlos K ^a   Tishler, Darren S ^a   Nicolau, David P ^a   Kuti, Joseph L ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; LINEZOLID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; BODY HEIGHT; BODY MASS; BODY SIZE; BODY WEIGHT; CLINICAL ARTICLE; COMPARTMENT MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; FLATULENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LEAN BODY WEIGHT; LEUKOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; MORBID OBESITY; MYCOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE;

ACETAMIDES; ADULT; AREA UNDER CURVE; BODY MASS INDEX; BODY WEIGHT; DRUG DOSAGE CALCULATIONS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; OBESITY, MORBID; OXAZOLIDINONES; PROSPECTIVE STUDIES; PROTEIN SYNTHESIS INHIBITORS; SEVERITY OF ILLNESS INDEX;

EID: 84874103695     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01453-12     Document Type: Article

References (28)

1. Ogden CL, Carroll MD, Kit BK, Flegal KM. 2012. Prevalence of obesity in the United State, 2009-2012. CDC NCHS data brief. no. 82. National Center for Health Statistics, Hyattsville, MD.
2. Olsen MA, Higham-Kessler J, Yokoe DS, Butler AM, Vostok J, Stevenson KB, Khan Y, Fraser VJ. 2009. Developing a risk stratification model for surgical site infection after abdominal hysterectomy. Infect. Control Hosp. Epidemiol. 30:1077-1083.
3. Serrano PE, Khuder SA, Fath JJ. 2010. Obesity as a risk factor for nosocomial infections in trauma patients. J. Am. Coll. Surg. 211:61- 67.
4. Waisbren E, Rosen H, Bader AM, Lipsitz SR, Rogers SO Jr, Eriksson E. 2010. Percent body fat and prediction of surgical site infection. J. Am. Coll. Surg. 210:381-389.
5. Bearden DT, Rodvold KA. 2000. Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics. Clin. Pharmacokinet. 38:415- 426.
6. Pfizer, Inc. 2012. Zyvox (linezolid) prescribing information. Pfizer, Inc., New York, NY.
7. Cheatham SC, Kays MB, Fleming MR, Shawa I. 2011. 51st Intersci. Conf. Antimicrob. Agents Chemother., abstr. A1-012.
8. Mersfelder TL, Smith CL. 2005. Linezolid pharmacokinetics in an obese patient. Am. J. Health Syst. Pharm. 53:464-467.
9. Stein GE, Schooley SL, Peloquin CA, Kak V, Havlichek DH, Citron DM, Tyrrell KL, Goldstein EJC. 2005. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann. Pharmacother. 39:427- 432.
10. Tsuji Y, Hiraki Y, Matsumoto K, Mizoguchi A, Sado S, Kobayashi T, Sakamoto S, Morita K, Yukawa E, Kamimura H, Karube Y. 2012. Evaluation of the pharmacokinetics of linezolid in an obese Japanese patient. Scand. J. Infect. Dis. 44:626-629.
11. Buerger C, Joukhadar C, Muller M, Kloft C. 2003. Development of a liquid chromatography method for the determination of linezolid and its application to in vitro and human microdialysis samples. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 796:155-164.
12. Leary R, Jelliffe R, Schumitzky A, Van Guilder M. 2001. An adaptive grid non-parametric approach to pharmacokinetic and dynamic (PK/PD) models, p 389 -394. In Proceedings of the 14th IEEE Symposium on Computer-Based Medical Systems. IEEE Computer Society, Bethesda, MD.
13. Meagher AK, Forrest A, Rayner CR, Birmingham MC, Schentag JJ. 2003. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob. Agents Chemother. 47:548- 553.
14. Plock N, Buerger C, Joukhadar C, Kljucar S, Kloft C. 2007. Does linezolid inhibit its own metabolism? Population pharmacokinetics as a tool to explain the observed nonlinearity in both healthy volunteers and septic patients. Drug Metab. Dispos. 35:1816 -1823.
15. D'Argenio DZ, Schumitzky A, Wang X. 2009. ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, CA.
16. Devine BJ. 1974. Gentamicin therapy. Drug Intell. Clin. Pharm. 8:650- 655.
17. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. 2005. Quantification of lean body weight. Clin. Pharmacokinet. 44:1051- 1065.
18. Andes D, van Ogtrop ML, Peng J, Craig WA. 2002. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob. Agents Chemother. 46:3484 -3489.
19. Stalker DJ, Jungbluth GL, Hopkins NK, Batts DH. 2003. Pharmacokinetics and tolerance of single- and multiple-dose oral and intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J. Antimicrob. Chemother. 51:1239 -1246.
20. Burkhardt O, Borner K, von der Hoh N, Koppe P, Pletz MW, Nord CE, Lode H. 2002. Single- and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy human volunteers. J. Antimicrob. Chemother. 50:707-712.
21. MacGowan AP. 2003. Pharmacokinetics and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J. Antimicrob. Chemother. 51(Suppl 2):17-25.
22. Housman ST, Kuti JL, Nicolau DP. 2011. Optimizing antibiotic pharmacodynamics in hospital-acquired and ventilator-acquired bacterial pneumonia. Clin. Chest Med. 32:439-450.
23. Smith BS, Yogaratnam D, Levasseur-Franklin KE, Forni A, Fong J. 2012. Introduction to drug pharmacokinetics i n the critically ill patient. Chest 141:1327-1336.
24. Varghese JM, Roberts JA, Lipman J. 2011. Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock. Crit. Care Clin. 27:19 -34.
25. Boselli E, Breilh D, Rimmele T, Djabarouti S, Toutain J, Chassard D, Saux MC, Allaouchiche B. 2005. Pharmacokinetics and intrapulmonary concentration of linezolid administered to critically ill patients with ventilator- associated pneumonia. Crit. Care Med. 33:1529 -1533.
26. Beringer P, Nguyen M, Hoem N, Louie S, Gill M, Gurevitch M, Wong-Beringer A. 2005. Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings. Antimicrob. Agents Chemother. 49:3676 -3681.
27. Keel RA, Schaeftlein A, Kloft C, Pope JS, Knauft RF, Muhlebach M, Nicolau DP, Kuti JL. 2011. Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis. Antimicrob. Agents Chemother. 55:3393-3398.
28. Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31- 41.